Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

969030

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, what recent steps the Government has taken to ensure that (a) negotiations between Vertex Pharmaceuticals and NHS England on access to Orkambi for people with cystic fibrosis proceed without further delay and (b) an agreement is reached between the two parties.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	171383
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171384 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

969031

registered interest
date	06/09/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, pursuant to the oral contribution of the Parliamentary Under-Secretary of State for Health and Social Care of 17 July 2018, Official Report, column 384, what progress the Government has made on access to Orkambi in England since Vertex Pharmaceuticals was called on to accept NHS England’s proposal to make that drug available to people with cystic fibrosis.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	171384
answer	answer is ministerial correction date of answer 14/09/2018 answer text <p>It is crucial that patients have access to the most effective and innovative medicines at a price that represents value to the National Health Service. While Ministers are keeping a very close eye on negotiations, it is the responsibility of NHS England as the commissioner and the National Institute for Health and Care Excellence (NICE) as the independent body that is responsible for making recommendations on whether drugs and other treatments represent a clinically and cost-effective use of NHS resources, to work with Vertex to agree a deal to secure the best outcome for patients and a price for Orkambi that is fair and responsible.</p><p> </p><p>NHS England has proposed its best offer ever for a drug. This offer, in the region of £500 million over five years, is the largest ever commitment of its kind in the 70-year history of the NHS. This would guarantee immediate and expanded access to both Orkambi and the drug Kalydeco for patients who need it. Whilst it is disappointing that Vertex has not taken up NHS England’s offer, we are pleased to hear that it has responded positively to NHS England’s and NICE’s latest offer to meet. The Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy), the Secretary of State for Health (Rt. hon. Matt Hancock MP) and I have and continue to urge Vertex to reconsider this fair offer.</p> answering member constituency Winchester answering member printed Steve Brine grouped question UIN 171383 question first answered 14/09/2018 13:32:27 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall

942539

registered interest
date	16/07/2018
answering body	Department of Health and Social Care
answering dept id	17
answering dept short name	Health and Social Care
answering dept sort name	Health and Social Care
hansard heading	Lumacaftor/ivacaftor
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health and Social Care, whether ensuring access to Orkambi for people with cystic fibrosis is a priority for his Department.
tabling member constituency	Thornbury and Yate
tabling member printed	Luke Hall
uin	164469
answer	answer is ministerial correction date of answer 20/07/2018 answer text <p>It is a key commitment of this Government to ensure that people with comparatively rarer conditions, like cystic fibrosis, get the same quality, safety and efficacy in medicines as those who have more common conditions.</p><p> </p><p>However, it is also necessary that Vertex prices Orkambi fairly and responsibly. That is why we must go through the right process with Vertex and NHS England, not the Government, working together to secure the best outcome for patients. NHS England has been in intensive discussions with Vertex to encourage it to price Orkambi at a level that would allow NHS England to fund its use without adversely impacting other patients. I and the Parliamentary Under-Secretary of State for Health (Lord O’Shaughnessy) have been keeping an extremely close eye on these discussions and wrote to Vertex in April, urging it to commit to pricing that is responsible and proportionate. I also re-iterated this message in the adjournment debate on 17 July, Official report, columns 383-4.</p> answering member constituency Winchester answering member printed Steve Brine question first answered 20/07/2018 10:10:54 answering member 4067 label Biography information for Steve Brine
tabling member	4450 label Biography information for Luke Hall